Trexquant Investment’s Crinetics Pharmaceuticals CRNX Stock Holding History

Trexquant Investment’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-62,679	Closed	-$3.2M	–	1598
2024 Q3	$3.2M	Buy	62,679 +40,141	+178%	+$2.07M	0.04%	644
2024 Q2	$1.01M	Buy	+22,538	New	+$1.04M	0.02%	998
2024 Q1	–	Sell	-22,644	Closed	-$806K	–	1479
2023 Q4	$806K	Buy	22,644 +15,233	+206%	+$467K	0.02%	900
2023 Q3	$220K	Buy	+7,411	New	+$153K	0.01%	1316
2023 Q2	–	Sell	-12,703	Closed	-$204K	–	1497
2023 Q1	$204K	Buy	+12,703	New	+$235K	0.01%	1314
2022 Q4	–	Sell	-24,509	Closed	-$481K	–	1421
2022 Q3	$481K	Buy	24,509 +10,493	+75%	+$214K	0.02%	828
2022 Q2	$261K	Buy	+14,016	New	+$280K	0.01%	1197

Other funds holding CRNX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Trexquant Investment's CRNX Position: Q4 2024 in Review

Trexquant Investment sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2024, closing a stake of 62,679 shares — an estimated $3.2M sold.

Trexquant Investment first reported a position in CRNX in Q2 2022 and held it in 7 quarters. The position peaked at $3.2M in Q3 2024. 247 funds tracked by Wall St. Rank hold CRNX as of Q4 2024.

Trexquant Investment reported no remaining Crinetics Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Trexquant Investment sold 62,679 Crinetics Pharmaceuticals shares in Q4 2024, an estimated $3.2M.
Trexquant Investment first reported a position in Crinetics Pharmaceuticals in Q2 2022 and held it in 7 quarters.
Trexquant Investment's Crinetics Pharmaceuticals position peaked at $3.2M in Q3 2024.
247 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2024.

Based on Trexquant Investment's 13F filing for Q4 2024, filed 12 Feb 2025.